Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Optimi Health Corp (CSE:OPTI)

4.550 +0.070 (+1.56%)
Delayed Quote Updated: 3:36 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Optimi Health Corp

BioMedNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 3 MDMA-Assisted Therapy Trial for PTSD
Via Investor Brand Network
NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 2 Psilocybin Trial for Major Depressive Disorder
Via Investor Brand Network
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial
Via Investor Brand Network
Topics Supply Chain
News headline image
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from... 
From OPTIMI HEALTH CORP.
Via GlobeNewswire
BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program
Via Investor Brand Network
News headline image
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
From OPTIMI HEALTH CORP.
Via GlobeNewswire
BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product
Via Investor Brand Network
News headline image
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
From OPTIMI HEALTH CORP.
Via GlobeNewswire
NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
Via Investor Brand Network
News headline image
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
From OPTIMI HEALTH CORP.
Via GlobeNewswire
PsychedelicNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
Via Investor Brand Network
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting
Via Investor Brand Network
News headline image
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
(May 20, 2026) - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and 
Via PressReach
Topics Regulatory Compliance
PsychedelicNewsBreaks – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift
Via Investor Brand Network
News headline image
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
(April 20, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic 
Via PressReach
News headline image
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Vancouver, British Columbia-March 16, 2026 - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE:8BN) (the "Company" or "Optimi"), a commercial-stage 
Via PressReach
Topics Regulatory Compliance
News headline image
Optimi Health Completes MD-MA Export for PTSD Treatment Under Australia’s Authorised Prescriber Scheme
(February 9, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychoactive 
Via PressReach
News headline image
Optimi Health Completes First 2026 Production of MD-MA and Psilo Capsules
(January 26, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug 
Via PressReach
News headline image
Early Warning Press Release in Accordance with National Instrument 62-103
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 110,000 common shares (each... 
Via Newsfile
Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP-grade psilocybin, synthetic psychedelic substances and... 
Via PressReach
News headline image
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
News headline image
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
Optimi Health and ATMA Journey Centers to Send a Clinical Trial Application to Health Canada for Phase I Natural Psilocybin and MDMA
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian company that makes natural, scalable, and easy-to-get psychedelic and functional mushrooms, as well as synthetic formulations, to help people... 
Via PressReach
Topics Supply Chain
Psychedelics May Make People Less Afraid of Death
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change... 
Via FinancialNewsMedia
Topics Supply Chain
Psychedelics Use Among Young Adults Reaches All-Time High
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,... 
Via FinancialNewsMedia
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study... 
Via FinancialNewsMedia
Topics Supply Chain
Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
Company utilizes green chemistry to stabilize natural product with higher yields Vancouver, BC – October 5, 2021 – Optimi Health Corp. (OTCQB: OPTHF) (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”),... 
Via FinancialNewsMedia
Topics Intellectual Property
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.